中国急性心力衰竭急诊临床实践指南

doi:10.3969/j.issn.1002-1949.2017.12.001

Chinese Journal of Critical Care Medicine

2017, Vol. 37

Issue (12): 1063-1074 DOI: 10.3969/j.issn.1002-1949.2017.12.001

Chinese clinical practice guidelines for the diagnosis and management of acute heart failure inemergency department

Abstract
Figure/Table
References (70)
Related Citation (15)

［1］Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study［J］. Circulation, 2007, 115(24):3103-3110. ［2］Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea［J］. J Am Coll Cardiol, 2010, 55(19):2062-2076. ［3］Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting［J］. BMJ, 2015, 350: h910. ［4］Kelder JC, Cramer MJ, Verweij WM, et al. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure［J］. J Card Fail, 2011, 17(9):729-734. ［5］Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis［J］. Heart, 2011, 97(12):959-963. ［6］Richards AM, Nicholls MG, Espiner EA, et al. B-type natriureic peptides and ejection fraction for prognosis after myocardial infarction［J］. Circulation, 2003, 107(22):2786-2792.  ［7］Kolin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriureic peptide in risk stratification of patient with congestive heart failure［J］. J Am Coll Cardiol, 2001, 38(7):1934-1941. ［8］Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism［J］. Eur Heart J, 2014, 35(45):3033-3069. ［9］Felker GM, Mentz RJ, Teerlink JR, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study［J］. Eur J Heart Fail, 2015, 17(12):1262-1270. ［10］Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure［J］. Circulation, 2007, 116(3): 249-257. ［11］Xue Y. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure［J］. Eur J Heart Fail, 2011, 13(1): 37-42. ［12］Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin familymember ST2 in patients with acute dyspnea: results from the PRIDE (Pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study［J］. J Am Coll Cardiol, 2007,50(7): 607-613. ［13］Aldous SJ. Richards AM. Troughton R. et al. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency departmentwithchest pain［J］. J Card Fail, 2012, 18(4):304-310. ［14］胡振, 张新超. 血清可溶性ST2评价老年急性心衰患者病情与预后的研究［J］. 中华急诊医学杂志，2016, 25(8):746-749. ［15］Maisel A. Increased 90-day mortality in patients with acute heart failure with elevated copeptin［J］. Circ Heart Fail, 2011, 4(5):613-620. ［16］Alehagen U, Dahlstrom U, Rehfeld JF, et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure［J］. JAMA, 2011, 305(20): 2088-2095. ［17］Wang CS, FitzGerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure［J］. JAMA, 2005, 294(15):1944-1956. ［18］Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care［J］. Am J Med, 1991, 90(3):353-359. ［19］Temporelli PL, Scapellato F, Eleuteri E, et al. Doppler echocardiography in advancd systolic heart failure: a noninvasive alternative to Swan-Ganz catheter［J］. Circ Heart Fail, 2010, 3(3):387. ［20］急诊超声标准操作规范专家组. 急诊超声标准操作规范［J］. 中国急救医学, 2013, 33(7): 577-591. ［21］Levy B. Lactate and shock state: the metabolic view［J］. Curr Opin Crit Care, 2006, 12(4):315-321. ［22］Jansen TC, van Bommel J, Schoonderbeek FJ, et al. LACTATE study group: Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial［J］. Am J Respir Crit Care Med, 2010, 182(6):752-761. ［23］Casserly B, Phillips GS, Schorr C, et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database［J］. Crit Care Med, 2015, 43(3):567-573. ［24］Manzano-Fernandez S, Januzzi JL, Boronat-Garcia M, et al. β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure［J］.J Am Coll Cardiol, 2011, 57(7): 849-858. ［25］de Geus HR, Bakker J, Lesaffre EM, et al. Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients［J］. Am J Respir Crit Care Med, 2011,183(7):907-914. ［26］Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies［J］. J Am Coll Cardiol, 2011, 57(17):1752-1761. ［27］Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure［J］. J Am Coll Cardiol, 2003, 41(10):1797-1804. ［28］Stevenson LW. Design of therapy for advanced heart failure［J］. Eur J Heart Fail, 2005, 7(3):323-331. ［29］Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients［J］. Am J Cardiol, 1967, 20(4):457-464. ［30］Wang GG, Wang SG, Qin J, et al. Characteristics, Management, and Outcomes of Acute Heart Failure in Emergency Department: A Multicenter Registry Study with 1-year Follow-up in a Chinese Cohort in Beijing［J］. Chin Med J, 2017, 130(16): 1894-1901. ［31］Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guides on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(4):384-416. ［32］Eskesen TG, Wetterslev M, Perner A. Systematic review including re-analyses of 1148 individual data sets of central venous pressure as a predictor of fluid responsiveness［J］. Intensive Care Med, 2016, 42(3): 324-332. ［33］L′Her E, Duquesne F, Girou E, et al. Noninvasive continuous positive airway pressure in elderly cardiogenic pulmonary edema patients［J］. Intensive Care Med, 2004, 30(5):882-888. ［34］Bellone A, Monari A, Cortellaro F, et al. myocardial infarction rate in acute pulmonary edema: noninvasive pressure support ventilation versus continuous positive airway pressure［J］. Crit Care Med, 2004, 32(9):1860-1865. ［35］Masip J. Non-invasive ventilation［J］. Heart Fail Review, 2007, 12(2):119-124. ［36］Ritchie JE,Williams AB,Gerard C，et al.Evaluation of a humidified nasal high-flow oxygen system, using oxygraphy, capnography and measurement of upper airway pressures［J］.Anaesth Intensive Care, 2011, 9(6):1103-1110. ［37］Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction［J］. Br Med J, 1976, 1(6018):1121-1123. ［38］Park JH, Balmain S, Berry C, et al. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction［J］. Heart, 2010, 96(7):533-538. ［39］De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock［J］. N Engl J Med, 2010, 362(9):779-789. ［40］Priori SG, Blomstro¨m-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europe Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)［J］. Eur Heart J, 2015, 36(41):2793-2867. ［41］Kirchof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS［J］. Eur J Cardiothorac Surg, 2016, 50(5):e1-e88. ［42］Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association［J］. Eur Heart J, 2013, 34(29):2281-2329. ［43］Felker GM, O′Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil［J］. Circ Heart Fail, 2009, 2(1):56-62. ［44］WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines［J］. Circulation, 2013, 128(16): e240. ［45］Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure［J］. N Engl J Med, 2011, 364(9): 797. ［46］Konstam MA, Gheorghiade M, Burnett JC Jr. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome tria［J］l. JAMA, 2007, 297:1319-1331. ［47］Cotter G, Metzkor E, Kaluski E, et al. Randomized trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema［J］. Lancet, 1998, 351(9100):389-393. ［48］Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry(ADHERE)［J］. J Am Coll Cardiol, 2005, 46(1):57-64. ［49］Publication committee for the VMAC investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial［J］. JAMA, 2002, 287(12):1531-1540. ［50］O′Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure［J］. N Eng J Med, 2011, 365(1):32-43. ［51］重组人脑利钠肽多中心研究协作组. 重组人脑利钠肽治疗心衰安全性和疗效的开放性随机对照多中心临床研究［J］. 中华心血管病杂志, 2011, 39(4):305-308. ［52］He JY, Wang J, Hua Q, et al. Safety and efficacy of urapidil and nitroglycerin in the treatment of elderly patients with acute heart failure: a randomized multicenter parallel-control study in China［J］. Int J Clin Exp Med, 2017, 10(6): 9729-9739. ［53］Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study［J］. J Am Coll Cardiol, 2003, 41(6):997. ［54］Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)［J］. J Am Coll Cardiol, 2005, 46(1):57. ［55］Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial［J］. Lancet, 2002, 360(9328):196-202. ［56］Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: A randomized, placebo-controlled, double-blind study (RUSSLAN)［J］. Eur Heart J, 2002, 23(18): 1422-1432. ［57］Mebazaa A, Nieminen MS, Packer M，et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial［J］. JAMA, 2007, 297(17):1883-1891. ［58］王雷, 崔亮, 魏嘉平, 等. 静脉注射左西孟旦治疗重度失代偿心衰患者的疗效分析［J］. 中华心血管病杂志, 2010, 38(6):527-530. ［59］张宇辉, 张健,卿恩明, 等. 国产左西孟旦与多巴酚丁胺治疗急性失代偿性心衰患者临床研究［J］. 中华心血管病杂志, 2012, 40(3):153-156. ［60］Peacock WF,Hollander JE,Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis［J］. Emerg Med J, 2008, 25(4):205-209. ［61］Jafri SM．Hypercoagulability in heart failure［J］．Semin Thromb Hemost，1997, 23(6)：543-545． ［62］Ahnert AM, Freudenberger RS．What do we know about anticoagulation in patients with heart failure［J］. Curr Opin Caldiol, 2008, 23(3): 228-232． ［63］Beemath A, Stein PD, Skaf E, et al．Risk of venous thromboembolism in patients hospitalized with heart failure［J］. Am J Caldiol, 2006, 98(6): 793-795． ［64］Klein L, O′connell JB．Thromboembolic risk in the patient with heart failure［J］. Curr Treat Options in Cardiovasc Med, 2007, 9(4): 310-317. ［65］Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure Results from COMET［J］. Eur J Heart Fail, 2007, 9(9): 901. ［66］Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program［J］. J Am Coll Cardiol, 2008, 52(3):190. ［67］Orso F, Baldasseroni S, Fabbri G, et al. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure［J］. Eur J Heart Fail, 2009, 11(1):77. ［68］Mentz RJ, Kjeldsen K, Rossi GP, et al. Decongestion in acute heart failure［J］. Eur J Heart Fail, 2014, 16(5):471-482. ［69］Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome［J］. N Engl J Med, 2012, 367(24):2296-2304. ［70］Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods［J］. Intensive Care Med, 2011, 37(2):290-301.